アミカシン
Based on 29 publication(s) in Google Scholar
Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 37517-28-5
- 分子式: C22H43N5O13
- 分子量:585.60
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Breast Cancer Compound Library
HY-L074
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
MedChemExpress（MCE）の使用を引用している文献 Amikacin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- EBioMedicine. 2025 May 30:117:105776. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 9:107551. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Int J Antimicrob Agents. 2018 Aug;52(2):269-271. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0094524. [Abstract]
- Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. [Abstract]
- Microbiol Spectr. 2026 Mar 30;14(5):e0147325. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- ACS Chem Biol. 2022 Jan 21;17(1):39-53. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- J Antimicrob Chemother. 2026 Jun 3;81(7):dkag204. [Abstract]
- J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Pathogens. 2025 Mar 21;14(4):302. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1493-1500. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Curr Microbiol. 2021 Dec 14;79(1):12. [Abstract]
- Int J Med Microbiol. 2023 Mar 28;313(2):151578. [Abstract]
- Authorea. 2025 Sep 17.
- bioRxiv. 2025 May 30.
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
|
Aminoglycoside |
TXNIP |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | CC50 |
>90 μg/mL
Compound: AMK
|
Cytotoxicity against mouse BMDM cells
Cytotoxicity against mouse BMDM cells
|
[PMID: 35307568] |
| Vero | IC50 |
>6.25 μg/mL
Compound: Amikacin
|
Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 28552337] |
| Vero | IC50 |
>62.5 μg/mL
Compound: Amikacin
|
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
|
[PMID: 23352268] |
Amikacin (30 µg, 0-24 h) has antibacterial activity, with a MIC50 value of 512 µg/mL against clinically isolated E. coli, and has a synergistic effect with imipenem (HY-B1369A), and the antibacterial effect is better when used in combination[1].
Amikacin (250 µg/mL, 0-24 h) inhibits the migration and invasion of human breast cancer cell line MDA-MB-231 cells by up-regulating the expression of TXNIP, indicating its anti-tumor potential[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human breast cancer cell line MDA-MB-231 cells
-
Concentration:250 µg/mL
-
Incubation Time:0-24 h
-
Result:Upregulated the expression of TXNIP to 4.87 times.
Amikacin (500 mg/kg/day for 8 days, s.c.) damages calpain activity in rat cochlea, promotes the degradation of sensory cells and neurons, and then leads to ototoxicity[4].
Amikacin (100 and 500 mg/kg/day for 10 days, s.c.) is nephrotoxic and its continued accumulation in rats can lead to kidney damage[5].
Pharmacokinetic Analysis in SD rats[5]
| Route | Dose (mg/kg) | Ka (h-1) | Ke1 (h-1) | t1/2 (h) | V (liter/kg) | AUC0-∞ (mg·h/mL) |
| s.c. | 100 | 1.20 | 6.77 | 0.10 | 0.28 | 53.0 |
| s.c. | 500 | 1.40 | 1.39 | 0.50 | 0.55 | 649.7 |